Takeda Cleared To Market Combo Drug For Treating Type 2 Diabetes
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it has received Japanese approval to expand the market for its Nesina (algogliptin) in combination with other drugs for treating type 2 diabetes. The other drugs in the combination are sulfonylurea and biguanide